At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics
- Mechanism of Action Calcium channel antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 14 Mar 2001 No-Development-Reported for Neurological disorders (Prevention) in USA (Unknown route)
- 15 May 1995 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)